Hepatic; renal

Cell culture and mouse studies suggest inhibiting ACMSD could help prevent non-alcoholic fatty liver disease (NAFLD) and acute kidney injury (AKI). In mouse primary hepatocytes, the ACMSD inhibitor TES-991 decreased palmitate-induced apoptosis compared with vehicle. In a human kidney epithelial cell line treated with the generic chemotherapy cisplatin, the ACMSD inhibitor TES-1025 decreased apoptosis. In a mouse model of diet-induced NAFLD, pretreatment with TES-991 decreased hepatic steatosis, liver inflammation and plasma markers of liver damage. In a mouse model of cisplatin-induced AKI, pretreatment with TES-1025 decreased kidney damage and loss of kidney function. Next steps by TES Pharma s.r.l. include clinical testing of TES-1025 and TES-991 in NAFLD and AKI patients. ...